Pinnacle Associates’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.75M | Sell |
70,435
-4,521
| -6% | -$326K | 0.06% | 251 |
|
|
2026
Q1 | $5.11M | Sell |
74,956
-8,475
| -10% | -$600K | 0.07% | 258 |
|
|
2025
Q4 | $6.34M | Sell |
83,431
-5,161
| -6% | -$375K | 0.08% | 224 |
|
|
2025
Q3 | $5.44M | Sell |
88,592
-3,916
| -4% | -$204K | 0.07% | 233 |
|
|
2025
Q2 | $4.52M | Sell |
92,508
-31,930
| -26% | -$1.52M | 0.07% | 253 |
|
|
2025
Q1 | $6.34M | Sell |
124,438
-5,585
| -4% | -$279K | 0.09% | 210 |
|
|
2024
Q4 | $5.87M | Sell |
130,023
-24,181
| -16% | -$1.03M | 0.08% | 220 |
|
|
2024
Q3 | $4.25M | Buy |
154,204
+300
| +0.2% | +$10K | 0.07% | 245 |
|
|
2024
Q2 | $4.71M | Sell |
153,904
-3,034
| -2% | -$98.3K | 0.07% | 248 |
|
|
2024
Q1 | $4.57M | Buy |
156,938
+2,734
| +2% | +$76.6K | 0.07% | 254 |
|
|
2023
Q4 | $4.25M | Sell |
154,204
-2,974
| -2% | -$68K | 0.07% | 248 |
|
|
2023
Q3 | $3.52M | Sell |
157,178
-6,822
| -4% | -$254K | 0.07% | 261 |
|
|
2023
Q2 | $6.67M | Sell |
164,000
-6,084
| -4% | -$298K | 0.12% | 195 |
|
|
2023
Q1 | $8.24M | Sell |
170,084
-2,519
| -1% | -$115K | 0.17% | 149 |
|
|
2022
Q4 | $6.59M | Sell |
172,603
-5,495
| -3% | -$228K | 0.14% | 172 |
|
|
2022
Q3 | $8.94M | Sell |
178,098
-5,878
| -3% | -$288K | 0.21% | 140 |
|
|
2022
Q2 | $7.37M | Sell |
183,976
-605
| -0.3% | -$21.2K | 0.16% | 160 |
|
|
2022
Q1 | $6.89M | Sell |
184,581
-8,100
| -4% | -$312K | 0.12% | 192 |
|
|
2021
Q4 | $7.67M | Sell |
192,681
-83
| -0% | -$3.18K | 0.13% | 172 |
|
|
2021
Q3 | $7.17M | Buy |
192,764
+30,930
| +19% | +$1.27M | 0.13% | 177 |
|
|
2021
Q2 | $6.84M | Buy |
161,834
+60,014
| +59% | +$2.57M | 0.12% | 177 |
|
|
2021
Q1 | $4.82M | Sell |
101,820
-11,195
| -10% | -$665K | 0.09% | 211 |
|
|
2020
Q4 | $6.9M | Sell |
113,015
-7,611
| -6% | -$449K | 0.14% | 166 |
|
|
2020
Q3 | $5.64M | Sell |
120,626
-5,363
| -4% | -$264K | 0.13% | 171 |
|
|
2020
Q2 | $6.39M | Sell |
125,989
-2,475
| -2% | -$122K | 0.16% | 156 |
|
|
2020
Q1 | $5.73M | Sell |
128,464
-20,824
| -14% | -$1.05M | 0.17% | 138 |
|
|
2019
Q4 | $7.17M | Sell |
149,288
-15,130
| -9% | -$643K | 0.16% | 159 |
|
|
2019
Q3 | $5.56M | Sell |
164,418
-7,670
| -4% | -$334K | 0.13% | 187 |
|
|
2019
Q2 | $7.74M | Sell |
172,088
-16,435
| -9% | -$649K | 0.18% | 156 |
|
|
2019
Q1 | $7.1M | Sell |
188,523
-4,235
| -2% | -$142K | 0.16% | 169 |
|
|
2018
Q4 | $6.62M | Sell |
192,758
-8,449
| -4% | -$304K | 0.17% | 160 |
|
|
2018
Q3 | $9.46M | Sell |
201,207
-33,775
| -14% | -$1.4M | 0.2% | 142 |
|
|
2018
Q2 | $7.93M | Sell |
234,982
-42,380
| -15% | -$1.32M | 0.16% | 165 |
|
|
2018
Q1 | $7.5M | Sell |
277,362
-12,070
| -4% | -$306K | 0.15% | 168 |
|
|
2017
Q4 | $4.83M | Sell |
289,432
-29,380
| -9% | -$497K | 0.09% | 214 |
|
|
2017
Q3 | $6.38M | Sell |
318,812
-8,110
| -2% | -$159K | 0.12% | 180 |
|
|
2017
Q2 | $5.99M | Sell |
326,922
-15,750
| -5% | -$212K | 0.12% | 180 |
|
|
2017
Q1 | $3.37M | Sell |
342,672
-8,750
| -2% | -$106K | 0.06% | 256 |
|
|
2016
Q4 | $3.83M | Sell |
351,422
-26,887
| -7% | -$282K | 0.08% | 232 |
|
|
2016
Q3 | $5.3M | Sell |
378,309
-9,330
| -2% | -$75.8K | 0.11% | 190 |
|
|
2016
Q2 | $2.72M | Sell |
387,639
-22,473
| -5% | -$165K | 0.06% | 261 |
|
|
2016
Q1 | $2.64M | Buy |
410,112
+30,020
| +8% | +$521K | 0.06% | 261 |
|
|
2015
Q4 | $12.3M | Buy |
380,092
+141,322
| +59% | +$4.16M | 0.26% | 105 |
|
|
2015
Q3 | $6.38M | Buy |
+238,770
| New | +$10.2M | 0.14% | 161 |
|
Other funds holding PTCT
RI
JT
Pinnacle Associates's PTCT Position: Q2 2026 in Review
Pinnacle Associates reduced its PTC Therapeutics (PTCT) stake by 6% in Q2 2026, selling an estimated $326K and leaving 70,435 shares worth $5.75M. The position accounts for 0.06% of the portfolio, ranked #251.
Pinnacle Associates first reported a position in PTCT in Q3 2015 and has held it in 44 quarters since. The position peaked at $12.3M in Q4 2015. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Pinnacle Associates held 70,435 shares of PTC Therapeutics worth $5.75M as of Q2 2026.
- Pinnacle Associates sold 4,521 PTC Therapeutics shares in Q2 2026, an estimated $326K.
- PTC Therapeutics made up 0.06% of Pinnacle Associates's portfolio in Q2 2026, its #251 holding.
- Pinnacle Associates first reported a position in PTC Therapeutics in Q3 2015 and has held it in 44 quarters since.
- Pinnacle Associates's PTC Therapeutics position peaked at $12.3M in Q4 2015.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.